 WOODCLIFF LAKE, N.J.--BUSINESS WIRE--Eagle Pharmaceuticals, Inc. Nasdaq: EGRX Eagle or the Company today announced that it has entered into a worldwide licensing agreement with Combioxin SA Combioxin, a clinical-stage biotechnology company based in Epalinges, Switzerland, for the commercial rights to CAL02, a novel first-in-class antitoxin agent ready for Phase 2b3 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs. Under the Agr 